Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents

Marta Cesca; Francesca Bizzaro; Massimo Zucchetti; Raffaella Giavazzi

doi:10.3389/fonc.2013.00259

Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents

Marta Cesca, Francesca Bizzaro, Massimo Zucchetti, Raffaella Giavazzi

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article › peer-review

Abstract

Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens. This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments. Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed. Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.

Original language	English
Article number	Article 259
Journal	Frontiers in Oncology
Volume	3 OCT
DOIs	https://doi.org/10.3389/fonc.2013.00259
Publication status	Published - 2013

Keywords

Angiogenesis inhibitors
Combination therapies
Drug delivery
Paclitaxel
Tumor microenvironment
Tyrosine kinase receptor inhibitors
Vascular disrupting agents

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.3389/fonc.2013.00259

Cite this

@article{615052b20b274621ba2efc808e2d59b4,

title = "Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents",

abstract = "Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens. This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments. Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed. Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.",

keywords = "Angiogenesis inhibitors, Combination therapies, Drug delivery, Paclitaxel, Tumor microenvironment, Tyrosine kinase receptor inhibitors, Vascular disrupting agents",

author = "Marta Cesca and Francesca Bizzaro and Massimo Zucchetti and Raffaella Giavazzi",

year = "2013",

doi = "10.3389/fonc.2013.00259",

language = "English",

volume = "3 OCT",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents

AU - Cesca, Marta

AU - Bizzaro, Francesca

AU - Zucchetti, Massimo

AU - Giavazzi, Raffaella

PY - 2013

Y1 - 2013

N2 - Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens. This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments. Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed. Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.

AB - Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens. This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments. Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed. Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.

KW - Angiogenesis inhibitors

KW - Combination therapies

KW - Drug delivery

KW - Paclitaxel

KW - Tumor microenvironment

KW - Tyrosine kinase receptor inhibitors

KW - Vascular disrupting agents

UR - http://www.scopus.com/inward/record.url?scp=84891060305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891060305&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00259

DO - 10.3389/fonc.2013.00259

M3 - Article

AN - SCOPUS:84891060305

SN - 2234-943X

VL - 3 OCT

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - Article 259

ER -

Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this